The UK Supreme Court has reshaped software patent assessment, moving away from Aerotel toward greater EPO harmonisation and confirming that an ANN is a “program for a computer.”
Two recent invalidity decisions show the risks of relying on online marketplace listings as prior art and demonstrate how design freedom shapes assessments of novelty and individual character.
The UPC Court of Appeal has clarified its inventive step framework. We compare the UPC’s approach with the EPO’s Problem-Solution analysis, highlighting key similarities and differences.
An analysis of T-628/24, where the General Court upheld revocation of Lego’s EU design for a modified plate, questioning how informed users and subtle design differences are assessed in modular systems.
The Brooklyn Beckham trade mark raises key questions about who controls a celebrity’s own name, the limits of the “own name” defence and the long-term risks of name-based trade mark registrations.
We reflect on a year of life sciences innovation, highlighting Clarivate’s Drugs to Watch 2025, emerging therapy trends, AI-driven R&D and the evolving patent strategies shaping the sector.
The General Court overturned an EUIPO revocation, holding that proof of genuine use must be assessed holistically. It rejected excessive evidential burdens and confirmed sales via distributors can suffice.
An analysis of how the EPO Boards of Appeal and the UPC Munich Local Division assessed inventive step for Sanofi’s cabazitaxel patent and why they reached opposite outcomes in parallel proceedings
A UK court confirmed Dryrobe’s trade marks remain valid, ruling that rival D-ROBE infringed them. The case highlights the need for brand owners to prevent their marks from becoming generic.
With the Grinch leading major UK Christmas ads, brands are leveraging character merchandising and tight IP licensing to stand out in a £12bn festive advertising season.
